25-(OH)VitD₃, as a Risk Indicator in Diagnosis of Adenocarcinoma

Title:25-(OH)VitD₃, as a Risk Indicator in Diagnosis of Adenocarcinoma

Volume: 14 Issue: 11

Author(s): Liang-Liang Cai, Hui-Ming Ye, Xiao-Nan Lv, Yun-long Wu, Huan-Jing Zhang, Li-Mou Zheng and Chi-Meng Tzeng

Affiliation:

Keywords: Adenocarcinoma, biomarker, risk assessment factor, 25-hydroxy-vitamin D₃.

Abstract: Vitamin D (VitD) comes from sunlight exposure and food intake. Apart from regulating calcium homeostasis and bone function, its levels also associate with the presence of development of adenocarcinoma. VitD can interact with VitD receptor (VDR), which heterodimerizes with retinoic X receptor (RXR) and then induces transcription of proteins that function in cell proliferation, differentiation, apoptosis, and angiogenesis. We reviewed and discussed the genes and their associated polymorphisms involved in the correlation between development of adenocarcinoma and VitD deficiency to highlight how VitD may be instrumental in cancerization. Furthermore, pilot epidemiological data show that the detection of 25-hydroxy-Vitamin D₃ ((36.5±10.7 nmol/L, n=129) vs (81.4±19.8 nmol/L, n=81)) can be a promising approach in cancer diagnosis. In this review, we suggest that 25-hydroxy-Vitamin D₃ can act as an indicator and/or risk assessment factor in early diagnosis, prognosis and treatment of adenocarcinoma.

Cite this article as:

Cai Liang-Liang, Ye Hui-Ming, Lv Xiao-Nan, Wu Yun-long, Zhang Huan-Jing, Zheng Li-Mou and Tzeng Chi-Meng, 25-(OH)VitD₃, as a Risk Indicator in Diagnosis of Adenocarcinoma, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113149990204